ALIVUS

Alivus Life Sciences Limited

Active pharmaceutical ingredients and CDMO services for chronic therapeutic areas

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

alivus.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹1309.50
Market cap
16,075 Cr
Stock P/E
26.7
P/B
4.83
Dividend yield
0.4%
ROE (FY26)
16.9%
ROCE (FY26)
22.7%
Operating margin (FY26)
28.3%
OCF / EBITDA (FY26)
70.9%
OCF / EBITDA (3Y)
63.6%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Alivus (Alivus Life Sciences) makes active pharmaceutical ingredients (APIs), most of them for chronic therapies, and sells them to customers in regulated and emerging markets, while also building a CDMO business for customers' new projects.

Company snapshot

33rdBy market cap

Ranked among 119 companies in Pharmaceuticals.

What we see

Positives
  • ✓Net margin of 22.1% — the business keeps a healthy share of every rupee it earns.
1 more signal from the filings.Sign in free to see them all

Statement tables · Standalone

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Standalone only

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales595 Cr573 Cr537 Cr589 Cr507 Cr642 Cr650 Cr602 Cr588 Cr673 Cr689 Cr640 Cr
Operating expenses (approx.)428 Cr400 Cr395 Cr429 Cr373 Cr452 Cr451 Cr430 Cr409 Cr442 Cr475 Cr429 Cr
EBITDA167 Cr173 Cr141 Cr159 Cr134 Cr190 Cr198 Cr172 Cr179 Cr231 Cr215 Cr212 Cr
OPM %28.1%30.1%26.4%27.1%26.5%29.7%30.5%28.6%30.5%34.4%31.1%33.1%
Other income5 Cr2 Cr3 Cr5 Cr9 Cr10 Cr10 Cr9 Cr15 Cr14 Cr23 Cr22 Cr
Interest0.40 Cr0.39 Cr0.36 Cr0.35 Cr0.34 Cr0.46 Cr1 Cr1 Cr1 Cr1 Cr1 Cr1 Cr
Depreciation13 Cr13 Cr15 Cr14 Cr15 Cr15 Cr16 Cr17 Cr18 Cr20 Cr20 Cr21 Cr
Profit before tax159 Cr161 Cr130 Cr150 Cr127 Cr185 Cr191 Cr163 Cr174 Cr198 Cr216 Cr212 Cr
Tax %25.3%26.1%24.5%25.8%25.2%26.0%25.8%25.4%25.3%24.3%24.6%24.6%
Net profit119 Cr119 Cr98 Cr111 Cr95 Cr137 Cr142 Cr122 Cr130 Cr150 Cr163 Cr160 Cr
EPS (₹)₹9.69₹9.69₹7.99₹9.10₹7.78₹11.18₹11.57₹9.91₹10.60₹12.25₹13.23₹13.04

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales886 Cr1,537 Cr1,885 Cr2,123 Cr2,161 Cr2,283 Cr2,387 Cr2,552 CrSign in free for the trailing twelve months
Operating expenses (approx.)639 Cr1,065 Cr1,294 Cr1,507 Cr1,519 Cr1,609 Cr1,704 Cr1,755 CrSign in free for the trailing twelve months
EBITDA248 Cr472 Cr591 Cr616 Cr642 Cr674 Cr683 Cr797 CrSign in free for the trailing twelve months
OPM %27.9%30.7%31.4%29.0%29.7%29.5%28.6%31.2%Sign in free for the trailing twelve months
Other income0.44 Cr12 Cr0.81 Cr15 Cr29 Cr12 Cr35 Cr60 CrSign in free for the trailing twelve months
Interest0.60 Cr34 Cr88 Cr28 Cr0.55 Cr2 Cr2 Cr5 CrSign in free for the trailing twelve months
Depreciation19 Cr29 Cr33 Cr38 Cr42 Cr53 Cr61 Cr75 CrSign in free for the trailing twelve months
Profit before tax228 Cr421 Cr471 Cr565 Cr629 Cr631 Cr654 Cr751 CrSign in free for the trailing twelve months
Tax %14.3%25.6%25.3%25.9%25.7%25.4%25.8%24.9%Sign in free for the trailing twelve months
Net profit196 Cr313 Cr352 Cr419 Cr467 Cr471 Cr486 Cr564 CrSign in free for the trailing twelve months
EPS (₹)₹24.64₹29.04₹32.61₹35.63₹38.11₹38.43₹39.63₹45.99Sign in free for the trailing twelve months
Dividend payout %———30.7%82.6%58.5%0.0%10.9%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital2 Cr2 Cr2 Cr25 Cr25 Cr25 Cr25 Cr25 Cr
Reserves86 Cr400 Cr751 Cr2,030 Cr2,114 Cr2,308 Cr2,793 Cr3,308 Cr
Borrowings0.02 Cr0.02 Cr——————
Other liabilities1,387 Cr1,324 Cr1,244 Cr417 Cr564 Cr518 Cr594 Cr651 Cr
Total liabilities1,475 Cr1,726 Cr1,997 Cr2,471 Cr2,702 Cr2,850 Cr3,411 Cr3,983 Cr
Fixed assets (net)450 Cr539 Cr565 Cr585 Cr775 Cr795 Cr943 Cr1,018 Cr
CWIP80 Cr11 Cr14 Cr92 Cr49 Cr101 Cr94 Cr273 Cr
Investments0.08 Cr0.08 Cr0.08 Cr0.08 Cr0.08 Cr0.08 Cr478 Cr780 Cr
Inventories401 Cr413 Cr513 Cr516 Cr604 Cr667 Cr674 Cr692 Cr
Trade receivables448 Cr639 Cr620 Cr673 Cr807 Cr765 Cr970 Cr1,073 Cr
Cash & bank2 Cr10 Cr116 Cr512 Cr284 Cr301 Cr71 Cr2 Cr
Other assets94 Cr114 Cr169 Cr93 Cr183 Cr221 Cr182 Cr144 Cr
Total assets1,475 Cr1,726 Cr1,997 Cr2,471 Cr2,702 Cr2,850 Cr3,411 Cr3,983 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity10 Cr195 Cr388 Cr598 Cr313 Cr414 Cr392 Cr565 Cr
Cash from investing-9 Cr-51 Cr-69 Cr-122 Cr-154 Cr-116 Cr-616 Cr-570 Cr
Cash from financing0.54 Cr-137 Cr-214 Cr-79 Cr-388 Cr-279 Cr-6 Cr-64 Cr
Net cash flow2 Cr8 Cr106 Cr397 Cr-228 Cr18 Cr-230 Cr-69 Cr
Free cash flow (OCF − Capex)1 Cr144 Cr322 Cr465 Cr143 Cr285 Cr225 Cr258 Cr

Ratios

MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %259.7%113.2%74.2%28.9%29.4%27.1%23.3%22.7%
ROE %221.9%77.9%46.7%20.4%21.8%20.2%17.2%16.9%
Debtor days184152120115136122148153
Inventory days223217191188200230233237
Days payable10210683112131127135128
Cash conversion cycle305263229191205225246262
OCF / EBITDA %4.2%41.3%65.7%97.0%48.8%61.3%57.4%70.9%
OCF / EBITDA % (3 years)——45.3%70.3%70.2%68.5%55.9%63.6%
Debt / equity0.00020.0001——0.00———
Current ratio0.670.891.154.603.674.374.975.21
Net debt / EBITDA-0.0082-0.02-0.20-0.83-0.44-0.45-0.10-0.0025